Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, a key pathological feature of MS. Preliminary imaging data have shown encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, according to the company.
This imaging approach could significantly enhance the development of MS therapies, including Quantum BioPharma's investigational candidate Lucid-MS. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the U.S. Food and Drug Administration in March 2026. Lucid-MS is a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models, addressing the underlying mechanism of MS.
The study's progress marks a critical step in validating a non-invasive method to monitor demyelination and remyelination in MS patients. Current imaging techniques often fail to capture gray matter lesions, which are increasingly recognized as important contributors to disability progression. If successful, the [¹⁸F]3F4AP tracer could provide a more comprehensive assessment of disease activity and treatment response.
Quantum BioPharma is a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on developing Lucid-MS. Additionally, Quantum invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty payments.
For more information on the press release, visit https://ibn.fm/4IZ0y. The latest news and updates relating to QNTM are available at https://ibn.fm/QNTM.
